HIMSSCast: The hurdles of AI in the pharma industry

AI is being increasingly used across the pharmaceutical lifecycle in the areas of clinical development, manufacturing, lab operations, and supply chain management.
The adoption of AI in pharma has intensified over the past two years, significantly impacting the industry.
Stringent regulations and increased government oversight, including a rising need for transparency in the U.S., at the state level, and from the EU, are placing greater emphasis on explainability, traceability, and control within the pharmaceutical sector as AI is embraced.
Pharma stands to benefit greatly as AI reduces the time it takes to bring new drugs to market, which might also help lower drug costs, consequently improving access to lifesaving medications, including orphan drugs and treatments for chronically underserved diseases.
Adopting new technologies and changing company culture is challenging due to stringent regulations and a resistance to new methods, which the pharma industry must overcome to embrace AI effectively.